The Morning Run speaks to Dodge about potential impeachment impact on markets, locking in gains as we get closer to the trade deadline as well as Dodge's asset allocation strategy for 2020. We also ask him about the consolidation in the pharmaceutical and biotechnology space and whether Dodge will be getting in on the Aramco's listing.